Crossmark

Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients

Crossref DOI link: https://doi.org/10.1007/s00415-021-10682-8

Published Online: 2021-07-01

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Volk, Timo https://orcid.org/0000-0001-9388-042X
Warnatz, Klaus

Marks, Reinhard

Urbach, Horst

Schluh, Gisela

Strohmeier, Valentina

Rojas-Restrepo, Jessica

Grimbacher, Bodo

Rauer, Sebastian
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (GR1617/14-1/iPAD; SFB1160/2_B5; RESIST–EXC 2155–Project ID 390874280; and CIBSS–EXC-2189–Project ID 390939984), SFB1160 TP A04)

Bundesministerium für Bildung und Forschung (GAIN 01GM1910A)

Universitätsklinikum Freiburg
License Information

Text and Data Mining valid from 2021-07-01

Version of Record valid from 2021-07-01
More Information

Article History

Received: 13 May 2021

Accepted: 21 June 2021

First Online: 1 July 2021

Declarations

:

: Declare no conflict of interest wrt the content of this manuscript.

: Not applicable.

: All patients received pembrolizumab on a compassionate-use basis after informed consent was obtained.

: All patients, guardians or next of kin have gave written informed consent for publication.

Document is current

Any future updates will be listed below